SWOG Update
October 2009
Contents  
Welcome to the October 2009 SWOG Update.

For all members and friends of the Southwest Oncology Group, the SWOG Update will keep you informed of what's happening with the Group. News to report? Send it to communications@swog.org.

View a one-page version for printing.
 
Chair's Corner  
How should we spell success?
Laurence H. Baker photo Questions of how we define success in cancer research and how costs should factor into that definition have been much in the news. [more]

Study Updates  

S0702: Zoledronic acid and ONJ risk
Patients taking zoledronic acid seem to face an increased risk of osteonecrosis of the jaw, or ONJ. S0702 seeks answers. [more]

Dawn Hershman, M.D. S0715: Does ALC prevent neuropathy?
Pain and numbness in hands and feet is a common side effect of taxane-based chemotherapy. Can the dietary supplement acetyl-L-carnitine prevent it? [more]

 
Don't Miss It  
Visualization of MCF-7 genome depicting somatic breast tumor chromosomal rearrangements. (Hampton, et al. Genome Res. 2009 Feb; 19(2); 167-177.) The War on Cancer: Raise the bar, or move the goal line?

Plenary Session
SWOG Fall 2009 Group Meeting
Friday, October 23, 12:15 - 2:45 pm
Gold Level, Regency B - D
Hyatt Regency Chicago
Share |

Did you know . . . ?

SWOG FY08 budget graph SWOG's total budget for fiscal year 2008 exceeded $45 million.


Got news to tell? Send it to communications@swog.org.